PD-1 antibody plus first-line chemotherapy for metastatic gastric cancer and gut bacteria
Official title: A Study on the Assessment of the Efficacy of PD-1 Monoclonal Antibody Combined With Chemotherapy in Metastatic Gastric Cancer Based on Gut Microbiota
Run by Fudan University · NCT07400354 · Data updated 2026-11-12
This project will try combining a PD-1 antibody with standard first-line chemotherapy in people with advanced gastric cancer to see if gut bacteria predict who benefits.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Fudan University Academic / other |
| Drugs / interventions | nivolumab, sintilimab, tislelizumab, pembrolizumab, fruquintinib, chemotherapy, immunotherapy |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | March 14, 2024 |
| Main results expected | March 14, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | February 10, 2026 |
| Trial ID | NCT07400354 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with histologically confirmed metastatic or locally advanced gastric cancer, ECOG 0–2, adequate organ function, at least one measurable lesion, no prior chemotherapy or immunotherapy, and planned for first-line PD-1 plus chemotherapy are ideal candidates.
✕Probably not a fit
Patients who have received prior palliative chemotherapy or immunotherapy, have poor performance status or organ dysfunction that fails eligibility labs, or cannot provide required stool samples are unlikely to benefit or enroll.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-center, open-label, phase II exploratory observational study will enroll 100 patients with metastatic or locally advanced gastric cancer who have not had prior chemotherapy or immunotherapy. Participants will receive a physician-chosen standard two-drug first-line chemotherapy regimen (FOLFOX, XELOX, or SOX) together with a PD-1 monoclonal antibody (nivolumab, sintilimab, tislelizumab, or pembrolizumab), with optional fruquintinib for certain sub-enrolled patients. Stool samples for gut microbiota profiling will be collected at baseline and at predefined on-treatment time points to identify microbial patterns associated with response or resistance to the combined therapy. Clinical outcomes and laboratory data will be recorded to correlate microbiome features with treatment efficacy and safety.
Why it matters
Potential benefit: If successful, the findings could help doctors use gut microbiome tests to predict who is likely to respond to PD-1 plus chemotherapy and personalize treatment.
How similar studies have gone: Prior research in melanoma and lung cancer has shown that gut microbiota can influence response to immune checkpoint inhibitors, but using microbiome signatures to predict benefit from PD-1 combined with chemotherapy in gastric cancer remains exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years, gender not restricted; * Eastern Cooperative Oncology Group (ECOG) performance status (PS) score 0-2, with -an expected survival period of more than 3 months; * Metastatic or locally advanced gastric cancer confirmed by cytology or histopathology; * Laboratory test data within 7 days before screening (including 7 days) should meet the following requirements: neutrophil count ≥ 1.5×109/L, platelet count ≥ 80×109/L, hemoglobin ≥ 80g/L, total serum bilirubin ≤ 1.5 times the upper limit of normal (ULN); ALT and AST ≤ 2.5 x ULN, if liver metastasis is present, ALT and AST ≤ 5 x ULN; albumin ≥ 30g/L; serum creatinine ≤ 1.5 x ULN or creatinine clearance rate (CCr) ≥ 60ml/min. * At least one evaluable lesion (according to RECIST 1.1 criteria); * No previous palliative chemotherapy and planned for first-line immunotherapy (nivolumab, sintilimab, tislelizumab, pembrolizumab as recommended by guidelines, specifically determined by the attending physician) combined with chemotherapy (FOLFOX, XELOX, SOX, specifically determined by the attending physician), and combination with fruquintinib is allowed (only for patients enrolled in the trial with the number HMPL-013-SH-GC103); * The subject (or their legal representative/guardian) must sign the informed consent form, indicating that they understand the purpose of this study, are aware of the necessary procedures, and are willing to participate in this study. Exclusion Criteria: * Pregnant or lactating women, and women of childbearing age who have not taken adequate contraceptive measures; * Patients with a history of other malignant tumors within 5 years, except for those with a history of cured cervical carcinoma in situ or non-melanoma skin cancer; Patients with primary brain tumors or central nervous system metastases that are not under control, and those with obvious intracranial hypertension or neuropsychiatric symptoms; * Patients with the following severe or uncontrolled diseases: severe heart disease, unstable condition despite treatment, myocardial infarction, congestive heart failure, unstable angina pectoris, significant pericardial effusion or unstable arrhythmia within 6 months before enrollment; definite neurological or psychiatric disorders, including dementia or epileptic seizures; severe or uncontrolled infections; active disseminated intravascular coagulation, or patients with obvious bleeding tendencies; * Patients with significant damage to important organs; * Patients with pleural effusion or ascites causing respiratory syndrome (≥CTCAE grade 2 dyspnea) requiring local treatment; * Other conditions where the investigator deems the patient unsuitable for participation in this trial; * Patients who have been taking probiotics or antibiotics for a long time.
Where it's running
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer
This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Overnight Temperature Regulation to Test Gut Health, Inflammation, and Circadian Rhythms
This study tests whether two weeks of using the Eight Sleep Pod at night can improve gut bacteria balance, lower inflammation, and strengthen daily temperature and blood pressure rhythms in postmenopausal women and age-matched men with poor sleep.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.